Skip to Content

Published on November 14, 2016

Public Reporting of Outcomes

Commission on Cancer Accredited Program

Concord Hospital Payson Center for Cancer Care is committed to sharing outcomes of our efforts to continuously evaluate and improve the quality of care we provide. Through feedback from patients, our own observations, national trends and other sources, we continuously identify ways in which the care we provide at the Center can be improved. The Payson Center is accredited by the American College of Surgeons Commission on Cancer. All accredited cancer programs regularly send de-identified data on certain measures to the National Cancer Data Base. The following chart shows data derived from that submission on five measures regarding breast cancer. If you have questions, please call (603) 230-6000.

Cancer Program Practice Profile Reports (CP3R)*: For Breast Cancers

Select Breast Measures

2014 Estimated Performance Rate

Image or palpation-guided needle biopsy (core or FNA) of the primary site is performed to establish diagnosis of breast cancer. (Quality Improvement) 100%
Radiation therapy is recommended or administered following any mastectomy within one year (365 days) of diagnosis of breast cancer for women with >= four positive regional lymph nodes. (Accountability) 100%
Combination chemotherapy is recommended or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB – III hormone receptor negative breast cancer. (Accountability) 100%
Radiation is administered within one year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer. (Accountability)       100%
Tamoxifen or third generation aromatase inhibitor is recommended or administered within one year (365 days) of diagnosis for women with AJCC T1c or state IB-III hormone receptor positive breast cancer. (Accountability) 90%
*Background: The Web-based Cancer Program Practice Profile Reports (CP3R) offer local providers comparative information to assess adherence to and consideration of standard care therapies for major cancers. This reporting tool provides a platform from which to promote continuous practice improvement to improve quality of patient care at the local level and also permits hospitals to compare their care for these patients relative to that of other providers.